.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
Recurrent C. difficile Infection
Treatment
About the Disease
C. difficile infection (CDI) is a bacterium of the intestine that causes life-threatening diarrhea. Although CDI can affect anyone, people over 65 are most vulnerable to the infection. Recurrent CDI is a serious condition afflicting many patients. CDI is considered recurrent when a patient experiences symptom onset and has a positive test in the 2–8-week period following the resolution of symptoms.
About our Patient Care
Our dedicated Care Team works with the physician's office and insurance on a patient's behalf to give our patients more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease-state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax, and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage care coordination between prescribers, sites of care, nurses, and patients to ensure dispense and drug delivery aligns with the date and location of service.
Financial Assistance
We successfully identify and assist in enrolling patients into all manufacturer co-pay and foundation support programs to minimize a potential financial burden to patients.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Supported Treatments
Click on the specialty drug name below to expand and see more information.
VOWST™ (fecal microbiota spores, live-brpk)
Brand Name | VOWST™ (fecal microbiota spores, live-brpk)
Manufacturer | Aimmune Therapeutics
Route of Administration | Oral
Approved Indication | Prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).
Self-Administration | Yes
Product Website | https://www.vowst.com/
VOWST is a registered trademark of Aimmune Therapeutics.
Partnering with Prescribers
Licensed prescribers can submit a completed enrollment form directly to our Admissions Team. We will begin the process and communicate with your office every step of the way.
